{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T16:50:46Z","timestamp":1761929446920,"version":"build-2065373602"},"reference-count":97,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","maturitas.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Maturitas"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.maturitas.2009.12.022","type":"journal-article","created":{"date-parts":[[2010,1,25]],"date-time":"2010-01-25T02:06:53Z","timestamp":1264385213000},"page":"340-347","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["New drug treatments for urinary incontinence"],"prefix":"10.1016","volume":"65","author":[{"given":"Dudley","family":"Robinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Cardozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.maturitas.2009.12.022_bib1","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of lower urinary tract function. Report from the standardisation committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurourol Urodynam"},{"key":"10.1016\/j.maturitas.2009.12.022_bib2","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1111\/j.1471-0528.1997.tb11006.x","article-title":"A new questionnaire to assess the quality of life of urinary incontinent women","volume":"104","author":"Kelleher","year":"1997","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib3","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/S0895-4356(00)00232-8","article-title":"A community-based epidemiological survey of female urinary incontinence: The Norwegian EPINCONT Study","volume":"53","author":"Hannestad","year":"2000","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.maturitas.2009.12.022_bib4","first-page":"S66","article-title":"Prevalence of overactive bladder in women: results from the NOBLE program","volume":"12","author":"Stewart","year":"2001","journal-title":"Int Urogynaecol J"},{"issue":"9","key":"10.1016\/j.maturitas.2009.12.022_bib5","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.maturitas.2009.12.022_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder and other lower urinary tract symptoms in five countries; results of the EPIC study","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"issue":"6A Suppl.","key":"10.1016\/j.maturitas.2009.12.022_bib7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0090-4295(97)00595-5","article-title":"The overactive bladder: pharmacologic basis of drug treatment","volume":"50","author":"Andersson","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.maturitas.2009.12.022_bib8","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0022-5347(01)65148-6","article-title":"Comparison of oxybutynin and it's active metabolite, N-desmethyl-oxybutynin, in the human detrusor and parotid gland","volume":"157","author":"Waldeck","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib9","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3109\/00498259209053145","article-title":"Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers","volume":"22","author":"Hughes","year":"1992","journal-title":"Xenobiotica"},{"key":"10.1016\/j.maturitas.2009.12.022_bib10","first-page":"256","article-title":"Oxybutynin chloride in the management of idiopathic detrusor instability","volume":"6","author":"Cardozo","year":"1987","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.maturitas.2009.12.022_bib11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1464-410X.1988.tb04356.x","article-title":"Oxybutynin: is it safe?","volume":"62","author":"Baigrie","year":"1988","journal-title":"Br J Urol"},{"issue":"6","key":"10.1016\/j.maturitas.2009.12.022_bib12","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0022-5347(05)68810-6","article-title":"Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence","volume":"161","author":"Anderson","year":"1999","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.maturitas.2009.12.022_bib13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0090-4295(99)00259-9","article-title":"Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence","volume":"54","author":"Gleason","year":"1999","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.maturitas.2009.12.022_bib14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0090-4295(03)00356-X","article-title":"Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence","volume":"62","author":"Dmochowski","year":"2003","journal-title":"Urology"},{"key":"10.1016\/j.maturitas.2009.12.022_bib15","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.juro.2008.11.125","article-title":"Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomised, double blind, placebo controlled, multicentre study","volume":"181","author":"Staskin","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1254\/fpj.94.145","article-title":"Effects of propiverine hydrochloride and its metabolites on isolated guinea pig urinary bladder","volume":"94","author":"Haruno","year":"1989","journal-title":"Folia Pharmacol Jpn"},{"key":"10.1016\/j.maturitas.2009.12.022_bib17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3109\/00365599509180578","article-title":"Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence","volume":"29","author":"Mazur","year":"1995","journal-title":"Scand J Urol Nephrol"},{"issue":"3","key":"10.1016\/j.maturitas.2009.12.022_bib18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/sj.sc.3100750","article-title":"Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia: a double-blind, placebo-controlled clinical trial","volume":"37","author":"Stoher","year":"1999","journal-title":"Spinal Cord"},{"issue":"Suppl. 1","key":"10.1016\/j.maturitas.2009.12.022_bib19","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1007\/PL00014139","article-title":"Medical treatment and medical side effects in urinary incontinence in the elderly","volume":"16","author":"Thuroff","year":"1998","journal-title":"World J Urol"},{"issue":"10","key":"10.1016\/j.maturitas.2009.12.022_bib20","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1345\/aph.18427","article-title":"Tolterodine use for symptoms of overactive bladder","volume":"33","author":"Ruscin","year":"1999","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.maturitas.2009.12.022_bib21","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0014-2999(97)89661-6","article-title":"Tolterodine\u2014a new bladder selective antimuscarinic agent","volume":"327","author":"Nilvebrant","year":"1997","journal-title":"Eur J Pharmacol"},{"issue":"13\u201314","key":"10.1016\/j.maturitas.2009.12.022_bib22","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0024-3205(97)00057-X","article-title":"Tolterodine\u2014a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data","volume":"60","author":"Nilvebrant","year":"1997","journal-title":"Life Sci"},{"key":"10.1016\/j.maturitas.2009.12.022_bib23","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003495-199855060-00008","volume":"55","author":"Hills","year":"1998","journal-title":"Tolterodine Drugs"},{"key":"10.1016\/j.maturitas.2009.12.022_bib24","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/BF02201987","article-title":"Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation","volume":"15","author":"Jonas","year":"1997","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.maturitas.2009.12.022_bib25","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0022-5347(05)68951-3","article-title":"Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity","volume":"161","author":"Millard","year":"1999","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.maturitas.2009.12.022_bib26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1464-410x.1998.00501.x","article-title":"Efficacy and safety of tolterodine in patients with detrusor instability: a dose ranging study","volume":"81","author":"Rentzhog","year":"1998","journal-title":"Br J Urol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib27","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0090-4295(97)00599-2","article-title":"Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a poled analysis","volume":"50","author":"Appell","year":"1997","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.maturitas.2009.12.022_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s00192-002-1009-0","article-title":"A new once daily formulation of tolterodine provides superior efficacy an is well tolerated in women with overactive bladder","volume":"14","author":"Swift","year":"2003","journal-title":"Int J Pelvic Floor Dysfunct"},{"issue":"3","key":"10.1016\/j.maturitas.2009.12.022_bib29","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0090-4295(00)01113-4","article-title":"Tolterodine once-daily: superior efficacy and tolerability in the treatment of overactive bladder","volume":"57","author":"Van Kerrebroeck","year":"2001","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.maturitas.2009.12.022_bib30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","article-title":"Prospective, randomised, double blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial","volume":"78","author":"Diokno","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.maturitas.2009.12.022_bib31","first-page":"984","article-title":"Determination of bioavailability of the quaternary ammonium compound trospium chloride in man from urinary excretion data","volume":"36","author":"Schladitz-Keil","year":"1986","journal-title":"Arzneimittel Forsch\/Drug Res"},{"issue":"5","key":"10.1016\/j.maturitas.2009.12.022_bib32","doi-asserted-by":"crossref","first-page":"223","DOI":"10.5414\/CPP38223","article-title":"Trospium chloride: an effective option for medical treatment of bladder overactivity","volume":"38","author":"Fusgen","year":"2000","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.maturitas.2009.12.022_bib33","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1046\/j.1464-410x.2000.00575.x","article-title":"Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial","volume":"85","author":"Cardozo","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.maturitas.2009.12.022_bib34","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.juro.2007.05.058","article-title":"Once daily Trospium chloride is effective and well tolerated for the treatment of overactive bladder; results from a multicentre phase III trial","volume":"178","author":"Staskin","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib35","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.urology.2007.11.008","article-title":"Trospium 60mg once daily (QD) for overactive bladder syndrome: results from a placebo controlled interventional study","volume":"71","author":"Dmochowski","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.maturitas.2009.12.022_bib36","article-title":"Extended release trospium chloride improves quality of life in overactive bladder","author":"Dmochowski","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.maturitas.2009.12.022_bib37","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1097\/01.ju.0000140729.07840.16","article-title":"Randomised, double blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder","volume":"172","author":"Cardozo","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1464-410X.2004.04561.x","article-title":"Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo and tolterodine controlled phase II dose-finding study","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.maturitas.2009.12.022_bib39","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.eururo.2004.11.004","article-title":"Long-term open label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome","volume":"47","author":"Haab","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib40","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib41","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1464-410X.2005.05294.x","article-title":"The role of urinary urgency and its measurement in the overactive bladder syndrome: current concepts and future prospects","volume":"95","author":"Chapple","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.maturitas.2009.12.022_bib42","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/j.1464-410X.2008.07939.x","article-title":"Solifenacin in the treatment of urgency and other symptoms of overactive bladder; results from a randomised, double-blind, placebo-controlled, rising dose trial","volume":"102","author":"Cardozo","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.maturitas.2009.12.022_bib43","first-page":"655","article-title":"Solifenacin improved warning time significantly compared to placebo in patients with overactive bladder","volume":"25","author":"Toglia","year":"2006","journal-title":"Neurourol Urodynam"},{"key":"10.1016\/j.maturitas.2009.12.022_bib44","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/01.ju.0000155798.78911.57","article-title":"Increased warning time with Darifenacin: a new concept in the management of urinary urgency","volume":"173","author":"Cardozo","year":"2005","journal-title":"J Urol"},{"issue":"Suppl 3","key":"10.1016\/j.maturitas.2009.12.022_bib45","first-page":"S441","article-title":"Solifenacin treatment reduces symptoms of overactive bladder in patients with residual urgency on tolterodine treatment: results of the VERSUS study","volume":"17","author":"Karram","year":"2006","journal-title":"Int Urogynaecol J"},{"key":"10.1016\/j.maturitas.2009.12.022_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjopharm.2006.03.004","article-title":"Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis","volume":"4","author":"Wagg","year":"2006","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.maturitas.2009.12.022_bib47","series-title":"Poster presentation. 38th Annual meeting of the international continence society","article-title":"Solifenacin is not associated with cognitive impairment or sedation in the elderly. The randomised double-blind SCOPE study","author":"Wesnes","year":"2008"},{"key":"10.1016\/j.maturitas.2009.12.022_bib48","series-title":"Poster presentation. 38th Annual meeting of the international continence society","article-title":"Solifenacin alone and with simplified bladder retraining in overactive bladder syndrome: The prospective randomised SOLAR study","author":"Mattiason","year":"2008"},{"key":"10.1016\/j.maturitas.2009.12.022_bib49","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.clinthera.2006.11.010","article-title":"Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the Vesicare Open Label Trial","volume":"28","author":"Garley","year":"2006","journal-title":"Clin Ther"},{"issue":"13\u201314","key":"10.1016\/j.maturitas.2009.12.022_bib50","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0024-3205(97)00047-7","article-title":"Discovery and development of selective M3 antagonists for clinical use","volume":"60","author":"Alabaster","year":"1997","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.maturitas.2009.12.022_bib51","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2004.01.008","article-title":"Darifenacin an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder","volume":"45","author":"Haab","year":"2004","journal-title":"Eur Urol"},{"issue":"Suppl","key":"10.1016\/j.maturitas.2009.12.022_bib52","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/S0022-5347(18)37749-8","article-title":"Darifenacin is well tolerated and provides significant improvement in the symptoms of overactive bladder: a pooled analysis of phase III studies","volume":"171","author":"Chapple","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib53","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.2174\/092986709789712835","article-title":"The design and development of Fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine","volume":"16","author":"Malhotra","year":"2009","journal-title":"Curr Med Chem"},{"issue":"5\/6","key":"10.1016\/j.maturitas.2009.12.022_bib54","first-page":"598","article-title":"A new effective and well tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a phase II controlled study","volume":"23","author":"Chapple","year":"2004","journal-title":"Neurourol Urodyn"},{"issue":"2","key":"10.1016\/j.maturitas.2009.12.022_bib55","first-page":"117","article-title":"Fesoterodine in non-neurogenic voiding dysfunction\u2014results on efficacy and safety in a phase III trial","volume":"5","author":"Chapple","year":"2006","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.maturitas.2009.12.022_bib56","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/j.1464-410X.2008.07907.x","article-title":"Comparison of Fesoterodine and tolterodine in patients with overactive bladder","volume":"102","author":"Chapple","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.maturitas.2009.12.022_bib57","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1464-410X.2008.07710.x","article-title":"Impact of Fesoterodine on quality of life: pooled data from two randomised trials","volume":"102","author":"Kelleher","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.maturitas.2009.12.022_bib58","series-title":"The pharmacological basis of theraputics","first-page":"387","article-title":"Drugs in the treatment of psychhiatric disorders","author":"Baldessarini","year":"1985"},{"key":"10.1016\/j.maturitas.2009.12.022_bib59","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/ageing\/15.5.299","article-title":"Double-blind study of imipramine and placebo for incontinence due to bladder instability","volume":"15","author":"Castleden","year":"1986","journal-title":"Age Aging"},{"key":"10.1016\/j.maturitas.2009.12.022_bib60","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0022-5347(17)60942-X","article-title":"Comparison of action of imipramine (Tofranil) and propantheline (Probanthine) on detrusor contraction","volume":"107","author":"Diokno Ac","year":"1972","journal-title":"J Urol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib61","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0022-3476(89)80885-6","article-title":"Nocturnal enuresis: an approach to treatment based on pathogenesis","volume":"114","author":"Norgaard","year":"1989","journal-title":"J Pediatrics"},{"key":"10.1016\/j.maturitas.2009.12.022_bib62","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1046\/j.1464-410X.2002.02791.x","article-title":"Efficacy of Desmopressin in the treatment of nocturia: a double blind placebo controlled studying men","volume":"89","author":"Mattiasson","year":"2002","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.maturitas.2009.12.022_bib63","first-page":"385","article-title":"Women take control; Desmopressin\u2014a drug for daytime urinary incontinence","volume":"21","author":"Robinson","year":"2002","journal-title":"Neurourol Urodyn"},{"year":"2006","series-title":"The management of urinary incontinence in women","author":"NICE Guideline 40","key":"10.1016\/j.maturitas.2009.12.022_bib64"},{"key":"10.1016\/j.maturitas.2009.12.022_bib65","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0022-3565(25)10548-X","article-title":"Effects of Duloxetine, a combined serotonin and norepineephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetised female cat","volume":"274","author":"Thor","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.maturitas.2009.12.022_bib66","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1067\/mob.2002.124840","article-title":"Duloxetine versus placebo in the treatment of stress urinary incontinence","volume":"187","author":"Norton","year":"2002","journal-title":"Am J Obstet Gynaecol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib67","first-page":"482","article-title":"Duloxetine vs. placebo in the treatment of stress urinary incontinence: a global phase III study","volume":"22","author":"Millard","year":"2003","journal-title":"Neurourol Urodynam"},{"key":"10.1016\/j.maturitas.2009.12.022_bib68","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/01.AOG.0000134525.86480.0f","article-title":"Pharmacological treatment of women awaiting surgery for stress urinary incontinence","volume":"104","author":"Cardozo","year":"2004","journal-title":"Obstet Gynaecol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib69","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/01.ju.0000154167.90600.c6","article-title":"A randomised controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence","volume":"173","author":"Ghoniem","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib70","first-page":"23","article-title":"The use of oestrogen in the treatment of dysuria and incontinence in postmenopausal women","volume":"14","author":"Salmon","year":"1941","journal-title":"Am J Obstet Gynaecol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib71","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0022-5347(17)66413-9","article-title":"Senile urethritis in women","volume":"78","author":"Youngblood","year":"1957","journal-title":"J Urol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib72","first-page":"116","article-title":"Postmenopausal hormones and incontinence: the Heart and Estrogen\/progestin Replacement Study","volume":"97","author":"Grady","year":"2001","journal-title":"Obstet Gynaecol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib73","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.AOG.0000107290.33034.6f","article-title":"Postmenopausal hormone therapy and risk of developing urinary incontinence","volume":"103","author":"Grodstein","year":"2004","journal-title":"Obstet Gynaecol"},{"issue":"6","key":"10.1016\/j.maturitas.2009.12.022_bib74","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1046\/j.1532-5415.2001.49160.x","article-title":"Effects of oral oestrogen and progestin on the lower urinary tract among female nursing home residents","volume":"49","author":"Ouslander","year":"2001","journal-title":"Am Geriatr Soc"},{"issue":"8","key":"10.1016\/j.maturitas.2009.12.022_bib75","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/jama.293.8.935","article-title":"Effects of estrogen with and without progestin on urinary incontinence","volume":"293","author":"Hendrix","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.maturitas.2009.12.022_bib76","unstructured":"Caine M, Raz S. The role of female hormones in stress incontinence. In: Proceedings of the 16th congress of the international society of urology, Amsterdam, The Netherlands."},{"key":"10.1016\/j.maturitas.2009.12.022_bib77","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3109\/00016348009155409","article-title":"The effects of oestrogens and gestagens on the urethral pressure profile in urinary continent and stress incontinent women","volume":"59","author":"Rud","year":"1980","journal-title":"Acta Obstet Gynaecol Scand"},{"key":"10.1016\/j.maturitas.2009.12.022_bib78","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1471-0528.1987.tb03152.x","article-title":"Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women","volume":"94","author":"Wilson","year":"1987","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib79","first-page":"135","article-title":"Urinary incontinence in postmenopausal women treated with oestrogens: a double-blind clinical trial","volume":"33","author":"Walter","year":"1978","journal-title":"J Urol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib80","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/0029-7844(96)00281-5","article-title":"Efficacy of oestrogen supplementation in the treatment of urinary incontinence","volume":"88","author":"Fantl","year":"1996","journal-title":"Obstet Gynaecol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib81","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1471-0528.1999.tb08372.x","article-title":"The effect of oestrogen supplementation on post-menopausal urinary stress incontinence: a double-blind, placebo controlled trial","volume":"106","author":"Jackson","year":"1999","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib82","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/0378-5122(94)90008-6","article-title":"Oestrogen and urinary incontinence in women","volume":"20","author":"Sultana","year":"1995","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2009.12.022_bib83","first-page":"57","article-title":"Urinary incontinence in 75 year old women. Effects of oestriol","volume":"93","author":"Samsicoe","year":"1985","journal-title":"Acta Obstet Gynaecol Scand"},{"key":"10.1016\/j.maturitas.2009.12.022_bib84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0378-5122(93)90028-G","article-title":"Oestriol in the treatment of postmenopausal urgency: a multicentre study","volume":"18","author":"Cardozo","year":"1993","journal-title":"Maturitas"},{"key":"10.1016\/j.maturitas.2009.12.022_bib85","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0378-5122(92)90246-Z","article-title":"Low dose oestradiol in the treatment of urogenital oestrogen deficiency\u2014a pharmacokinetic and pharmacodynamic study","volume":"15","author":"Nilsson","year":"1992","journal-title":"Maturitas"},{"issue":"2","key":"10.1016\/j.maturitas.2009.12.022_bib86","first-page":"281","article-title":"Does low dose vaginal oestradiol improve frequency and urgency in postmenopausal women","volume":"3","author":"Benness","year":"1992","journal-title":"Int Urogynaecol J"},{"key":"10.1016\/j.maturitas.2009.12.022_bib87","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0028-2243(92)90059-8","article-title":"Low dose 17\u03b2-oestradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study","volume":"44","author":"Eriksen","year":"1992","journal-title":"Eur J Obstet Gynaecol Reprod Biol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib88","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1471-0528.2000.tb10408.x","article-title":"Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms","volume":"107","author":"Lose","year":"2000","journal-title":"Br J Obstet Gynaecol"},{"issue":"3","key":"10.1016\/j.maturitas.2009.12.022_bib89","first-page":"V","article-title":"Estrogen treatment for symptoms of an overactive bladder, results of a meta analysis","volume":"12","author":"Cardozo","year":"2001","journal-title":"Int J Urogynaecol"},{"issue":"4","key":"10.1016\/j.maturitas.2009.12.022_bib90","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001405.pub2","article-title":"Oestrogen therapy for urinary incontinence in post-menopausal women","author":"Cody","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.maturitas.2009.12.022_bib91","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000138768","article-title":"Experimental hyperreflexia: effect of intravesical administration of various agents","volume":"42","author":"Levin","year":"1991","journal-title":"Pharmacology"},{"key":"10.1016\/j.maturitas.2009.12.022_bib92","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0090-4295(97)00595-5","article-title":"The overactive bladder: pharmacologic basis of drug treatment","volume":"50","author":"Andersson","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.maturitas.2009.12.022_bib93","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000280321","article-title":"Spontaneous phasic activity of the detrusor: a cause of uninhibited contractions in unstable bladder","volume":"35","author":"Laval","year":"1980","journal-title":"Urol Int"},{"key":"10.1016\/j.maturitas.2009.12.022_bib94","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.eururo.2006.01.037","article-title":"Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: a randomized double-blind placebo controlled study (ZD0947IL\/0004)","author":"Chapple","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib95","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.juro.2006.08.018","article-title":"Efficacy and safety of a neurokinin-1 receptor antagonist in postmenopausal women with overactive bladder with urge urinary incontinence","volume":"176","author":"Green","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.maturitas.2009.12.022_bib96","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1517\/13543784.16.7.999","article-title":"Overactive bladder treatments in early phase clinical trials","volume":"16","author":"Colli","year":"2007","journal-title":"Exp Opin Invest Drugs"},{"key":"10.1016\/j.maturitas.2009.12.022_bib97","first-page":"239","article-title":"Clinical proof of concept study (Blossom) shows novel \u03b23 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder","volume":"7","author":"Chapple","year":"2008","journal-title":"Eur Urol Suppl"}],"container-title":["Maturitas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512209004927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378512209004927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:49:40Z","timestamp":1759913380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378512209004927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0378512209004927"],"URL":"https:\/\/doi.org\/10.1016\/j.maturitas.2009.12.022","relation":{},"ISSN":["0378-5122"],"issn-type":[{"type":"print","value":"0378-5122"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New drug treatments for urinary incontinence","name":"articletitle","label":"Article Title"},{"value":"Maturitas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.maturitas.2009.12.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}